Therefore, predicting TMB and key mutations in ccRCC is a critically needed research task due to its high clinical relevance: first, TMB is a strong predictor of response to cancer immunotherapy‐related prognosis;4, 5, 8 second, TMB and key mutations such as VHL are highly associated with clinical outcomes.9, 10. This evidence concerns the gene VHL and nonpapillary renal cell carcinoma.